Research Analysts’ Weekly Ratings Changes for Bicara Therapeutics (BCAX)

Several brokerages have updated their recommendations and price targets on shares of Bicara Therapeutics (NASDAQ: BCAX) in the last few weeks:

• 3/31/2026 – Bicara Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a “neutral” rating on the stock.
• 3/31/2026 – Bicara Therapeutics had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an “equal weight” rating on the stock.
• 3/31/2026 – Bicara Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.
• 3/31/2026 – Bicara Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.
• 3/31/2026 – Bicara Therapeutics had its price target raised by HC Wainwright from $40.00 to $42.00. They now have a “buy” rating on the stock.
• 3/25/2026 – Bicara Therapeutics is now covered by Bank of America Corporation. They set a “buy” rating and a $35.00 price target on the stock.

Insider Activity

In related news, CEO Claire Mazumdar sold 36,766 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $19.17, for a total transaction of $704,804.22. Following the transaction, the chief executive officer directly owned 339,392 shares in the company, valued at approximately $6,506,144.64. This represents a 9.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Ivan Hyep sold 13,555 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $18.22, for a total transaction of $246,972.10. Following the transaction, the chief financial officer owned 145,355 shares in the company, valued at $2,648,368.10. The trade was a 8.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 137,969 shares of company stock valued at $2,586,198. 15.50% of the stock is currently owned by company insiders.

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.